Esmolol

Perioperative hypertension and tachyarrhythmia are common acute and severe diseases in clinical practice. If not controlled in time, they will significantly increase the risk of cardiovascular events. As an ultra-short-acting selective β1 adrenoceptor blocker, esmolol is one of the core drugs in this field. Its mechanism of action is to competitively block β1 receptors on cardiomyocytes, reducing heart rate, myocardial contractility and myocardial oxygen consumption. Meanwhile, due to the presence of ester bonds in its structure that are easily hydrolyzed by esterases, its half-life is only 9 minutes, and the effect subsides rapidly after drug withdrawal, which facilitates clinical dose titration. This drug is indicated for the urgent control of perioperative hypertension, sinus tachycardia and supraventricular tachyarrhythmia, and has good safety for high-risk patients with concomitant coronary heart disease and cardiac insufficiency. It is a standing first-aid drug in anesthesiology departments, cardiology departments and ICUs.

The global esmolol market size has maintained steady growth in recent years. The market size in 2023 was approximately USD 280 million, with the Chinese market accounting for more than 35% and a compound annual growth rate of 6.2%. The domestic market is dominated by generic drugs, and the overall competitive landscape is relatively concentrated, with the top 3 enterprises accounting for nearly 70% of the market share. With the implementation of the national centralized procurement policy in recent years, the price of esmolol injection has dropped by more than 80%, and the clinical accessibility has been greatly improved, driving the annual growth of the demand for its active pharmaceutical ingredient to remain steadily above 10%.

The original research enterprise of esmolol is Baxter Healthcare Corporation, with the original brand name Brevibloc®. Its core compound patent expired globally in 1994. The main dosage form approved for the original drug is injection, with specifications covering 10ml:100mg and 5ml:250mg. It has now been included in the *Catalogue of Reference Preparations of Chemical Drugs* of China and the FDA reference preparation catalogue. Up to now, more than 15 domestic enterprises have obtained A status for their esmolol active pharmaceutical ingredients through CDE registration, and the number of corresponding approved preparation manufacturers exceeds 20. The domestic supply system has been very mature. (Data as of June 2025, please refer to the official website of CDE for the latest information)

CATO can provide a full set of impurity reference standards for esmolol API. The full series of products strictly comply with the regulatory requirements of the Chinese Pharmacopoeia, FDA and other regulations. Most products are in stock all year round. Orders placed before 16:00 can be shipped on the same day, which can fully meet the reference standard supply needs of pharmaceutical enterprises throughout the entire cycle from R&D and declaration to mass production quality control.